Meeting abstract
https://doi.org/10.26800/LV-144-supl6-PS06
The efficacy of venetoclax in relapsed and treatment-refractory acute myeloid leukemia
Josipa Dropuljić
Anđela Deak
Nadira Duraković
Abstract
The most common acute leukemia in adults is acute myeloid leukemia (AML) and it is mainly
treated with cytarabine and anthracyclines. Although this combination of drugs is effective for most patients, some
of them experience relapse and require new strategies. Recently venetoclax, a drug that blocks B-cell lymphoma-2
(Bcl-2) protein and leads to programmed cell death, was approved for use in the treatment of AML. Here we present
a patient with relapsed AML after allogeneic hematopoietic stem cell transplantation (HSCT) who was successfully
treated with venetoclax.
Keywords
acute myeloid leukemia; haploidentical transplantation; venetoclax
Hrčak ID:
290725
URI
Publication date:
8.12.2022.
Visits: 531 *